Abstract
Obesity prevalence continues to increase in both adults and children worldwide and greatly contributes to increased morbidity and mortality. Although there are some anti-obesity drugs globally available for clinical use, their inadequate effectiveness coupled with safety concerns sometimes discourage the widespread use of anti-obesity medication. Because of its prolonged therapeutic effect and low frequency of administration, a therapeutic vaccine may be an attractive strategy for the prevention and treatment of obesity. Over the last two decades, several attempts have been made to develop vaccines for the control of obesity. Animal studies have shown that vaccines targeting ghrelin, glucose-dependent insulinotropic polypeptide, adipocytes, somatostatin, and adenovirus 36 successfully led to a reduction in weight gain without serious adverse effects. This chapter provides an overview of recent progress toward a therapeutic vaccine against obesity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ambuhl PM, Tissot AC, Fulurija A et al (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25:63–72
Andrade S, Pinho F, Ribeiro AM et al (2013) Immunization against active ghrelin using virus-like particles for obesity treatment. Curr Pharm Des 19:6551–6558
Asakawa A, Inui A, Fujimiya M et al (2005) Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18–24
Atkinson RL, Dhurandhar NV, Allison DB et al (2005) Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes 29:281–286
Azegami T, Yuki Y, Sawada S et al (2017) Nanogel-based nasal ghrelin vaccine prevents obesity. Mucosal Immunol 10:1351–1360
Azegami T, Yuki Y, Nakahashi R et al (2018) Nanogel-based nasal vaccines for infectious and lifestyle-related diseases. Mol Immunol 98:19–24
Baum HB, Biller BM, Finkelstein JS et al (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890
Bourinbaiar AS, Jirathitikal V (2010) Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices. Vaccine 28:2763–2768
Bray GA, Fruhbeck G, Ryan DH et al (2016) Management of obesity. Lancet 387:1947–1956
Date Y, Shimbara T, Koda S et al (2006) Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metab 4:323–331
Dhurandhar NV, Whigham LD, Abbott DH et al (2002) Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J Nutr 132:3155–3160
Faria AC, Veldhuis JD, Thorner MO et al (1989) Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. J Clin Endocrinol Metab 68:535–541
Flegal KM, Kit BK, Orpana H et al (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309:71–82
Fulurija A, Lutz TA, Sladko K et al (2008) Vaccination against GIP for the treatment of obesity. PLoS One 3:e3163
Ghelardoni S, Carnicelli V, Frascarelli S et al (2006) Ghrelin tissue distribution: comparison between gene and protein expression. J Endocrinol Investig 29:115–121
Haffer KN (2012) Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice. J Anim Sci Biotechnol 3:21
Heymsfield SB, Wadden TA (2017) Mechanisms, pathophysiology, and management of obesity. N Engl J Med 376:254–266
Kenchaiah S, Evans JC, Levy D et al (2002) Obesity and the risk of heart failure. N Engl J Med 347:305–313
Kim KR, Nam SY, Song YD et al (1999) Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res 51:78–84
Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660
Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31:58–83
Lai QG, Jiang BQ, Zhou XH et al (2010) The effects and mechanism of xenogeneic adipocyte vaccine for the prevention of obesity in rats. J Int Med Res 38:1700–1707
Lamichhane A, Azegami T, Kiyono H (2014) The mucosal immune system for vaccine development. Vaccine 32:6711–6723
Lyons MJ, Faust IM, Hemmes RB et al (1982) A virally induced obesity syndrome in mice. Science 216:82–85
Maurer P, Jennings GT, Willers J et al (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35:2031–2040
McClean PL, Irwin N, Cassidy RS et al (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746–E1755
Miyawaki K, Yamada Y, Ban N et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738–742
Na HN, Nam JH (2014) Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36. Int J Obes 38:1470–1474
Nakazato M, Murakami N, Date Y et al (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198
Nochi T, Yuki Y, Takahashi H et al (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9:572–578
Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578
Rogers PM, Fusinski KA, Rathod MA et al (2008) Human adenovirus Ad-36 induces adipogenesis via its E4 orf-1 gene. Int J Obes 32:397–406
Sadry SA, Drucker DJ (2013) Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 9:425–433
Srivastava G, Apovian CM (2018) Current pharmacotherapy for obesity. Nat Rev Endocrinol 14:12–24
Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407:908–913
Vangipuram SD, Sheele J, Atkinson RL et al (2004) A human adenovirus enhances preadipocyte differentiation. Obes Res 12:770–777
Vangipuram SD, Yu M, Tian J et al (2007) Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by fat cells. Int J Obes 31:87–96
Vivante A, Golan E, Tzur D et al (2012) Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med 172:1644–1650
Vizcarra JA, Kirby JD, Kim SK et al (2007) Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol 33:176–189
Wadden TA, Webb VL, Moran CH et al (2012) Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 125:1157–1170
Wang YC, McPherson K, Marsh T et al (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378:815–825
Wilson PW, D’Agostino RB, Sullivan L et al (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867–1872
Wortley KE, Anderson KD, Garcia K et al (2004) Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 101:8227–8232
Yang J, Brown MS, Liang G et al (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132:387–396
Zigman JM, Nakano Y, Coppari R et al (2005) Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115:3564–3572
Zorrilla EP, Iwasaki S, Moss JA et al (2006) Vaccination against weight gain. Proc Natl Acad Sci U S A 103:13226–13231
Acknowledgments
This work was supported in part by the Mochida Memorial Foundation for Medical and Pharmaceutical Research.
Conflict of Interest
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Azegami, T., Itoh, H. (2019). Immunotherapy for Obesity. In: Nakagami, H. (eds) Therapeutic Vaccines as Novel Immunotherapy. Springer, Singapore. https://doi.org/10.1007/978-981-32-9628-2_4
Download citation
DOI: https://doi.org/10.1007/978-981-32-9628-2_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9627-5
Online ISBN: 978-981-32-9628-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)